🔗 Share this article

As the US continues making sweeping revisions to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has focused upon alleged fatalities following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Agency leaders were set to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US out of step with a large portion of the international standard with insufficient data for benefit. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A Shift at the Agency

This interim role could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

The new acting director has often pushed for ending some childhood vaccine recommendations in the US so as to align more like the Danish model, a society with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has no apparent background in drug development, approval processes or administrative roles, which has been typical for previous directors of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “understand regulatory frameworks and the research of drug development”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who headed the center have had.”

CDER has an immense range of responsibilities at the FDA, Woodcock pointed out.

“Many people just focuses on the new drug program, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and each of these have to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership component to the job, which supervises in excess of 5,000 employees. “It’s a massive management job, if you do it right,” Woodcock said.

Response and Contentious Policies

When asked about inquiries about Høeg’s credentials and whether this selection represents greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions are based on incorrect presumptions”.

“This background is consistent with the responsibilities of her job,” the spokesperson explained, pointing to the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious expedited therapy clearance system that reportedly concerned her predecessors. “How are these therapies being chosen for this fast-track system? Who makes the choices?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed rules of all drugs, aside from immunizations.”

Public Past Work on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, past, some experts observe. She released a study using non-validated crowd-sourced reports to determine the rate of heart inflammation following COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership featured altering regulations for novel immunizations and ending “unnecessary” vaccines, she said after the election on a online show. At the agency, Høeg has reportedly proposed preventing adolescent males from obtaining Covid vaccinations.

“She is an complete ideologue who commences with her beliefs and reverse-engineers to fit the data in a very deceptive, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|